Edition:
United States

Profile: iCo Therapeutics Inc (ICOTF.PQ)

ICOTF.PQ on OTC Markets Group

0.07USD
26 Apr 2019
Change (% chg)

-- (--)
Prev Close
$0.07
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
--
52-wk High
$0.00
52-wk Low
$0.00

iCo Therapeutics Inc. (iCo) is a Canada-based biotechnology company principally focused on the identification, development and commercialization of drug candidates to treat sight-and life-threatening diseases. The Company principally focuses on in-licensing drug candidates with a clinical history, and re-dose, reformulate and develop drug candidates for the treatment of sight-and life-threatening diseases. The Company's product candidates include iCo-007, iCo-008 and an Oral AmpB Delivery System. The Company has initiated Phase II clinical trial for iCo-007. iCo-008 is a human monoclonal antibody that is offered to treat sight threatening forms of allergic conjunctivitis by neutralizing eotaxin-1, a ligand to the chemokine receptor CCR3. Oral AmpB Delivery System is a toxic option for the treatment of serious systemic fungal infections. The Company has completed pre-clinical studies for iCo's Oral AmpB Delivery System.

Company Address

iCo Therapeutics Inc

6th Floor, 777 Hornby Street
VANCOUVER   BC   V6Z 1S4
P: +1604.6573882
F: +1604.6029699

Company Web Links